Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nasr, Samya
NCT05641298: Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations	Withdrawn	2	80	US	Sodium Fusidate, ACG-701, ARV-1801, Placebo	Aceragen	Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation	09/23	09/23
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003	Completed	1	51	US	ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.	Anagram Therapeutics, Inc.	Exocrine Pancreatic Insufficiency	07/24	07/24
NCT04994301: Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients	Recruiting	N/A	48	US	Lung T1 MRI	University Hospitals Cleveland Medical Center	Cystic Fibrosis	12/24	12/24
STOP PEDS RCT, NCT06654752: Streamlined Treatment of Pulmonary Exacerbations in Pediatrics	Recruiting	N/A	430	Canada, US	Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed	University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation	Cystic Fibrosis	12/27	02/29
Moore, Brooke
STOP PEDS RCT, NCT06654752: Streamlined Treatment of Pulmonary Exacerbations in Pediatrics	Recruiting	N/A	430	Canada, US	Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed	University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation	Cystic Fibrosis	12/27	02/29